Alnylam Advances New Innovations in RNAi Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Alnylam Pharma (ALNY) Announces Presentation of Positive ALN-TTRsc02 Data as ATTR Amyloidosis Treatment
October 14, 2015 7:03 AM EDTAlnylam Pharma (NASDAQ: ALNY) announced today that it presented key pre-clinical data and provided program guidance for ALN-TTRsc02, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis). The new data were presented at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held October 11 14, 2015, in Leiden, Netherlands. In pre-clinical studies, including those in non-human primates (NHPs), ALN-TTRsc02 achieved potent and highly durable knockdown of serum TTR of up to 99% with multi-month durability achieved after just a single dose, supportive of a potentially once quarterly dose regimen. Based on... More
Alnylam (ALNY) Continues to Expand RNAi Capabilities; FBR Affirms at 'Outperform'
October 13, 2015 12:21 PM EDTFBR affirmed its Outperform rating and $180 price target on Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) after the company announced advancement of innovations in RNAi therapeutics with presentation of scientific data on two new platform technologies. First, the company presented data on its Bis-RNAi platform that... More
